> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Justice Department Tells Vanda It Is Weighing A Civil Complaint Over HETLIOZ Practices
- URL: https://www.bullished.co/justice-department-tells-vanda-it-is-weighing-a-civil-complaint-over-hetlioz-practices-a7b9f056/
- Published: 2026-10-29T12:21:04.000Z
- Updated: 2026-10-29T12:21:04.000Z
- Description: Vanda also lost its HETLIOZ patent suits in Delaware and set a November 2027 generic entry date for Fanapt, its 10-Q shows.
- Author: Matteo Parrino
- Tags: SEC Filings, VNDA, Industry: Healthcare

The Justice Department told [Vanda Pharmaceuticals](https://www.bullished.co/tag/vnda/) in October that it is considering a civil complaint over the company's historical HETLIOZ practices, according to a [10-Q filed Thursday](https://www.sec.gov/Archives/edgar/data/0001347178/000134717826000002/vnda-20260930.htm?ref=bullished.co). Vanda, a biopharmaceutical company that sells the schizophrenia drug Fanapt, the sleep-disorder drug HETLIOZ and the multiple sclerosis drug PONVORY, says no complaint has been filed.

## A False Claims Act inquiry moves forward

The notice follows a Civil Investigative Demand the Justice Department sent in October 2024 as part of an investigation of possible False Claims Act violations. It sought documents on HETLIOZ practices; Vanda says it complied fully with that demand and with a later request for testimony.

Should the government sue, Vanda says it will contest every allegation. It says it cannot predict the timing of any proceeding. The [prior quarter's 10-Q](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026053855/vnda-20260630.htm?ref=bullished.co) did not carry this passage.

## HETLIOZ patent suits lose in Delaware

In September, the Delaware federal court granted summary judgment of non-infringement to Teva and Apotex on the '129 and '556 patents, relying partly on a June 2026 Supreme Court decision in Hikma v. Amarin. Vanda says it is evaluating future options.

In a separate Fanapt settlement in October, Vanda granted Alembic a non-exclusive license to sell a generic version in the U.S. from November 2, 2027, when the '610 patent expires.

## HETLIOZ sales and the cash balance

HETLIOZ net sales fell 21% to $43.2 million for the first nine months. The company says they may decline in future periods, potentially significantly, because of generic competition. Third-quarter HETLIOZ sales of [$21.7 million included](https://markets.ft.com/data/announce/detail?dockey=600-202610281601PR%5FNEWS%5FUSPRX%5F%5F%5F%5FPH83656-1&ref=bullished.co) about $7.0 million for orders shipped June 29 that arrived July 1.

Total revenue rose 24% to $69.8 million in the quarter, led by Fanapt at $38.8 million. Cash and marketable securities stood at $140.5 million, against $263.8 million at December 31, 2025\. Vanda says that is enough for at least the next 12 months, and it expects full-year 2026 revenue above $240 million, according to its [earnings release](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026067886/vnda8-k10282026exhibit991.htm?ref=bullished.co).

The FDA hearing on HETLIOZ for jet lag disorder is scheduled for December 14 to 18, 2026, and the FDA's target decision date on Quimilza is December 12.

### Sources

- [10-Q Filing — Vanda Pharmaceuticals (VNDA)](https://www.sec.gov/Archives/edgar/data/0001347178/000134717826000002/vnda-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Vanda Pharmaceuticals (VNDA), Q2 FY2026 filed 2026-08-06 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026053855/vnda-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, vnda8-k10282026exhibit991.htm) — Vanda Pharmaceuticals, filed 2026-10-28](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026067886/vnda8-k10282026exhibit991.htm?ref=bullished.co) — SEC EDGAR
- [Vanda Pharmaceuticals GAAP EPS of -$0.37 beats by $0.31, revenue of $69.82M beats by $0.7M (NASDAQ:VNDA) | Seeking Alpha](https://seekingalpha.com/news/4659608-vanda-pharmaceuticals-gaap-eps-of-0%5F37-beats-by-0%5F31-revenue-of-69%5F82m-beats-by-0%5F7m?ref=bullished.co) — seekingalpha.com
- [Vanda (VNDA) Q3 2026 Earnings Call Transcript](https://finance.yahoo.com/healthcare/articles/vanda-vnda-q3-2026-earnings-054403129.html?ref=bullished.co) — Yahoo Finance
- [Vanda: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/vanda-q3-earnings-snapshot/616-1071f1d4-07a3-4a00-bcd8-d50466f1d709?ref=bullished.co) — Associated Press
- [Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates](https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-vnda-reports-q3-202003116.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610281601PR%5FNEWS%5FUSPRX%5F%5F%5F%5FPH83656-1&ref=bullished.co) — Financial Times

### More on Vanda Pharmaceuticals

- [Vanda's Hetlios Sales Jumped 289% On Pharmacy Stocking, And The CFO Says They May Fall](https://www.bullished.co/vandas-hetlios-sales-jumped-289-on-pharmacy-stocking-and-the-cfo-says-they-may-fall-7d91d83c/)
- [Vanda Blames 'Migration To The Mean' As Nereus Vomiting Cut Falls To 27% From 50%](https://www.bullished.co/vanda-blames-migration-to-the-mean-as-nereus-vomiting-cut-falls-to-27-from-50-e1bb3e2a/)
- [Vanda Revenue Climbs 24% To $69.8 Million As Spending Drops 18%, But Cash Falls To $140.5 Million](https://www.bullished.co/vanda-revenue-climbs-24-to-69-8-million-as-spending-drops-18-but-cash-falls-to-140-5-22c6db75/)

[All Vanda Pharmaceuticals (VNDA) coverage →](https://www.bullished.co/tag/vnda/)